Alflutop injections 2ml 5 vials

Alflutop contains hyaluronic acid, chondroitin-4-sulfate, choidroitin-6-sulfate, dermatan sulfate, keratan sulfate, low molecular weight polypeptides, free amino acids, trace elements - Na, K, Ca, Mg, Fe, Cu, Zn, Mn. The complex composition of the drug makes it similar to the matrix of hyaline cartilage.

Pack of 10 ampoules of 1 ml. 1 ml contains 10 mg of extract.

PHARMACHOLOGIC EFFECT

Alflutop - the original chondroprotector, is a purified, standardized and stabilized extract from 4 species of small marine fish.

Alflutop has chondroprotective, anti-inflammatory, analgesic, regenerative, trophic activity.

Alflutop has a pronounced anti-inflammatory and analgesic effect in various forms of osteoarthritis. The experiment has shown that the drug prevents the destruction of macromolecular structures of normal tissues, stimulates recovery processes in the interstitial tissue and tissue of the articular cartilage. The anti-inflammatory effect and tissue regeneration are based on the inhibition of the activity of hyaluronidase and the normalization of the biosynthesis of hyaluronic acid. Both of these effects are synergistic and determine the end result - anti-inflammatory effect and activation of regenerative processes in tissues (in particular, restoration of the cartilage structure).

Alflutop has a complex mechanism of action. Its components:

• directly replace glycosaminoglycans in the proteoglycan structure of cartilage tissue;
• regulate the metabolism of functioning chondrocytes, stimulating the biosynthesis of hyaluronic acid and other components of the cartilage matrix, type II collagen;
• regulate the proliferation of chondrocytes;
• inhibit the activity of hyaluronidase, which loses the ability to depolymerize hyaluronic acid (the main component of connective tissue that acts as an intercellular "glue" that helps preserve tissue structure), and other enzymes involved in the destruction of the extracellular matrix, such as elastase, collagenase, lysosomal hydrolases, serine proteinases, etc .;

• inhibit the biosynthesis of inflammatory mediators;
• mask secondary antigenic determinants and suppress chemotaxis;
• suppress the synergistic action of enzymes and free oxygen radicals;
• have an antioxidant effect by stimulating the activity of superoxide dismutase;
• improve microcirculation in the subchondral parts of the bone and synovial tissue;
• suppress lipid synthesis.

The chondroprotective and anti-inflammatory effect of Alflutop has been proven in experimental and clinical studies by biochemical, histochemical, X-ray, radioisotope methods, and by the results of magnetic resonance imaging.

The drug affects the prevention of neoplasm of blood vessels in damaged cartilage by inhibiting the factor of angiogenesis and, according to preclinical studies, has a gastroprotective effect.

Alflutop has no toxicity, immunogenicity and teratogenicity. The drug is well tolerated, including by patients with gastrointestinal or cardiovascular diseases. The clinical effect of treatment with Alflutop is achieved according to the literature in 70-90% of patients and is expressed in a decrease in pain, a decrease in joint swelling, a gradual increase in joint mobility, partial recovery and significant improvement in the structure of articular cartilage, an increase in the density of the subchondral bone, an increase in the level of hyaluronic acid in the synovial liquids.

ALFLUTOP INDICATIONS FOR USE IN SPORT

• The recovery period after surgical interventions on the musculoskeletal system;
• Prevention of arthrosis of small joints (chronic sports injury);
• Fibromyalgia (as a result of sports activities);
• Degenerative-dystrophic lesions of the joints against the background of metabolic osteopathy;
• Traumatic dystosis;
• Osteoarthritis;
• Sports injury of the spine;
• Osteochondrosis;
• Spondylosis;
• Periarthritis.

Alflutop is used for degenerative rheumatic diseases: coxarthrosis, gonarthrosis, arthrosis of the small joints of the arms and legs, osteochondrosis and spondylosis.

ALFLUTOP DOSING MODE

Alflutop can be administered intramuscularly, intra-articularly, paravertebrally, periarticularly, into pain points in fibromyalgia.

Administration schemes can be as follows.

In case of involvement of multiple joints: deep intramuscular injection of 1 ml daily for 20 days.

In case of involvement of large joints in the process: intra-articular 2 ml - in each affected joint - 1 time in 3 days (6 injections), followed by intramuscular injection of 1 ml daily for 20 days. Clinical studies confirm the greatest effectiveness of this option, which is characterized by a faster and more lasting therapeutic effect.

In case of spinal lesions: paravertebral 1 ml on each side 1 time in 2-3 days (5 injections), followed by intramuscular injection of 1 ml daily for 20 days. Repetition of the course of treatment is advisable in 3-6 months.

For polyosteoarthritis and osteochondrosis, the drug is administered deeply intramuscularly, 1 ml per day (20 injections in total).

A combination of intra-articular and intramuscular methods of administration is possible. It is advisable to repeat the course of treatment after 6 months.

CONTRAINDICATIONS

There are no contraindications.